51 results about "Angiotensin Receptor Antagonists" patented technology

The present invention discloses a novel crystalline form of an angiotensin receptor antagonist and neutral endopeptidase inhibitor supramolecular complex. The novel crystalline form of the supramolecular complex has high water solubility and good stability. Experiments show that the moisture absorption and intrinsic dissolution extent and speed are superior to those of a conventional crystalline supramolecular complex.

The invention provides a pharmaceutical composition which comprises calcium channel blockers of a medicinal dose, angiotensin II receptor antagonists of a medicinal dose, one or more of B vitamins of a medicinal dose and pharmaceutically acceptable carriers, wherein the calcium channel blockers are selected from amlodipine, felodipine, israbipine, nicardipine, nifedipine, nisoldipine, nitrendipine, lacidipine, diltiazem or verapamil; the angiotensin II receptor antagonists are selected from candesartan, telmisartan, losartan, valsartan, irbesartan, eprosartan, tasosartan or olmesartan; and the B vitamins are selected from one or more of vitamin B6, vitamin B12, folic acid and calcium leucovorin. The pharmaceutical composition of the invention can improve the curative effect of the hypotensor, enhance the target organ protecting action of the hypotensor, and reduce the morbidity of complications of angina, myocardial infarction and the like.

A specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of hypertension.

A 4,6-dihydrofurano[3,4-d] imidazole-6-ketone derivative, its pharmacological receptible salt, and the preparing process of said derivatives are disclosed. Said compound can be used as the intermediate for synthesizing the antagon of angiotensin II receptor.

The present invention provides a an angiotensin receptor antagonist and creatine phosphate sodium complex and uses thereof, wherein the complex comprises an angiotensin receptor antagonist and creatine phosphate sodium, a molar ratio of the angiotensin receptor antagonist to the creatine phosphate sodium is 1:1-2, and the angiotensin receptor antagonist is selected from valsartan, losartan, irbesartan, telmisartan, eprosartan, candesartan, olmesartan, saprisartan, tasosartan, and elisartan. According to the present invention, the complex is formed by compounding the angiotensin receptor antagonist and the creatine phosphate sodium, and provides the unexpected double effect and the synergistic effect for treatment of heart failure and high blood pressure, the cocrystallization salt hydrate formed by linking the hydrogen bond has the stable characteristic, the pharmacokinetic property is significantly provided, and the positive application prospects are provided in the fields of anti-high blood pressure treatment and anti-heart failure treatment.

The invention relates to a sustained release preparation of a novel prescription for treating hypertension and the preparing method thereof. The novel prescription comprises a heart selective Beta1 receptor blocker metoprolol and an angiotensin II receptor antagonist (sartan drugs). The sustained release preparation consists of delayed release part and rapid release part, wherein the heart selective Beta1 receptor blocker metoprolol is the delayed release part, with first hour releasing 25-45%, fourth hour releasing 40-75% and eighth hour releasing over 75%; the angiotensin II receptor antagonist (sartan drugs) is the rapid release part, with 45 minutes dissolution over 75%. The composition has both rapid and prolonged action. The invention discloses in vitro drug release characteristics and preparation method thereof.

Solid oral dosage forms, especially tablets, of a pharmaceutical composition comprising a supramolecular complex can be formed from a direct compression process or a compaction process such as roller compaction. Such solid oral dosage forms feature an immediate release profile that allows for fast release of the therapeutic agent. A particularly useful supramolecular complex is trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate]hemipentahydrate.

The invention provides an angiotensin receptor antagonist and milrinone compound and a use thereof. The compound comprises an angiotensin receptor antagonist and milrinone, the angiotensin receptor antagonist and milrinone can be directly mixed, or can be indirectly connected through hydrogen bonds, and cocrystallized sodium hydrate formed by using the hydrogen bonds have stable properties and substantially improved pharmacokinetic properties. The action mechanisms of the angiotensin receptor antagonist and milrinone are different, but the compound formed by the angiotensin receptor antagonist and milrinone have unexpected synergism, so the compound has positive application prospect in the anti-heart failure and anti-hypertension field.

The invention provides a compound of an angiotensin receptor blocker and levosimendan and use of the compound. The compound is composed of the angiotensin receptor blocker and levosimendan, which can be mixed directly or be connected indirectly through a hydrogen bond, wherein a co-crystallized sodium hydrate formed by connection through hydrogen bond is more stable in property; and the pharmacokinetic properties are improved significantly; the action mechanisms of the angiotensin receptor blocker and the levosimendan are different, but the formed compound has an unexpected synergistic effect and has positive application prospects in the anti-heart failure and anti-hypertensive treatment field.

The present application belongs to the technical field of drug application, relates to a treatment method using a complex of an angiotensin II receptor antagonist metabolite and an NEP inhibitor, and specifically relates to the dosage of the drug.

The invention discloses 6-pyridin benzimidazole indole derivatives and a preparation method thereof. The compounds are novel angiotensin II receptor antagonists and can be used for prevention and treatment of cardiovascular, cerebrovascular and renal-vascular diseases like hypertension, coronary heart disease and pulmonary arterial hypertension.

The invention relates to a pharmaceutical composition containing angiotensin II receptor antagonist, statin lipid-lowering drugs and folic acid compound. The pharmaceutical composition contains medicinal dose of angiotensin II receptor antagonist, medicinal dose of statin lipid-lowering drugs, medicinal dose of folic acid composite and a carrier acceptable in pharmaceutics. The invention also relates to an application of the pharmaceutical composition in preparing medicines for preventing and treating or retarding high blood pressure accompanied by dyslipidemia and the application thereof in preparing medicines for treating target organ damage caused by the high blood pressure accompanied by dyslipidemia; in addition, the invention further relates to the application of the pharmaceutical composition in preparing medicines for lowering risk of cardiovascular and cerebrovascular events caused by high blood pressure accompanied by dyslipidemia. The invention belongs to the pharmaceutical field. With the implementation of the invention, the pharmaceutical composition with special usage, provided to the patients, can improve compliance of the patients, bring convenience to the patients to take medicines and reduce medical expenses, thus enjoying good market prospect.

The invention relates to application of combination of an angiotensin converting enzyme inhibitor and an angiotensin receptor antagonist in preparation of medicine for treating osteoarthritis, and further relates to a corresponding medicine composition.

The invention relates to a new application of a compound of an angiotensin II receptor antagonist metabolite and an NEP inhibitor, which belongs to the technical field of pharmaceutical application, and specifically relates to the application of the compound in the preparation of medicines for salt-sensitive hypertension.